Cargando…

Long-Acting Injectable Cabotegravir for HIV Prevention: What Do We Know and Need to Know about the Risks and Consequences of Cabotegravir Resistance?

PURPOSE OF REVIEW: Cabotegravir is a potent integrase strand transfer inhibitor (INSTI) recently approved as a long-acting injectable formulation for HIV prevention (CAB-LA). We summarize what is known about cabotegravir pharmacokinetics, activity, and emergence of resistance from in vitro, macaque...

Descripción completa

Detalles Bibliográficos
Autores principales:	Parikh, Urvi M., Koss, Catherine A., Mellors, John W.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer US 2022
Materias:	The Science of Prevention (R Heffron and K Ngure, Section Editors)
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9508028/ https://www.ncbi.nlm.nih.gov/pubmed/36112336 http://dx.doi.org/10.1007/s11904-022-00616-y

Ejemplares similares

Lessons Learned from Longer Acting Reversible Contraception Applied to Longer Acting HIV Prevention Technologies
por: Logan, Rachel, et al.
Publicado: (2021)

Introducing the Dapivirine Vaginal Ring in Sub-Saharan Africa: What Can We Learn from Oral PrEP?
por: Bhavaraju, Neeraja, et al.
Publicado: (2021)

Novel Platforms for Biomedical HIV Prevention Delivery to Key Populations — Community Mobile Clinics, Peer-Supported, Pharmacy-Led PrEP Delivery, and the Use of Telemedicine
por: Rousseau, E., et al.
Publicado: (2021)

Multi-level Interventions to Promote Oral Pre-exposure Prophylaxis Use Among Adolescent Girls and Young Women: a Review of Recent Research
por: Irungu, Elizabeth, et al.
Publicado: (2021)

Risk-Based Screening Tools to Optimise HIV Testing Services: a Systematic Review
por: Ong, J. J., et al.
Publicado: (2022)

HIV Testing Uptake According to Opt-In, Opt-Out or Risk-Based Testing Approaches: a Systematic Review and Meta-Analysis
por: Soh, Qi Rui, et al.
Publicado: (2022)

Using Behavioral Economics to Support PrEP Adherence for HIV Prevention
por: Roy Paladhi, Unmesha, et al.
Publicado: (2022)

Examining the Use of HIV Self-Testing to Support PrEP Delivery: a Systematic Literature Review
por: Kiptinness, Catherine, et al.
Publicado: (2022)

Formulation and pharmacology of long-acting cabotegravir
por: Trezza, Christine, et al.
Publicado: (2015)

Cabotegravir
Publicado: (2022)

Long‐acting injectable cabotegravir: implementation science needed to advance this additional HIV prevention choice
por: Schmidt, Heather‐Marie Ann, et al.
Publicado: (2022)

Safety and efficacy of long-acting injectable cabotegravir as preexposure prophylaxis to prevent HIV acquisition
por: Fonner, Virginia A., et al.
Publicado: (2023)

Experiences to date with the logistical management of long-acting cabotegravir and rilpivirine
por: Johnson, Kamile, et al.
Publicado: (2022)

Acceptability of Long-Acting Injectable Cabotegravir (CAB LA) in HIV-Uninfected Individuals: HPTN 077
por: Tolley, Elizabeth E., et al.
Publicado: (2020)

Pharmacokinetics and Drug–Drug Interactions of Long-Acting Intramuscular Cabotegravir and Rilpivirine
por: Hodge, Daryl, et al.
Publicado: (2021)

Cabotegravir—Global Access to Long-Acting Pre-exposure Prophylaxis for HIV
por: Pepperrell, Toby, et al.
Publicado: (2022)

Evaluating cabotegravir/rilpivirine long-acting, injectable in the treatment of HIV infection: emerging data and therapeutic potential
por: Fernandez, Cristina, et al.
Publicado: (2019)

Evaluation of the effect of UGT1A1 polymorphisms on the pharmacokinetics of oral and long-acting injectable cabotegravir
por: Patel, Parul, et al.
Publicado: (2020)

Securing accelerated access to long‐acting injectable cabotegravir for HIV prevention in low‐ and middle‐income countries
por: Jenkins, Sarah Y., et al.
Publicado: (2023)

Effect of Cabotegravir on Cardiac Repolarization in Healthy Subjects
por: Lou, Yu, et al.
Publicado: (2016)

Pharmacokinetics of Cabotegravir in Subjects with Severe Renal Impairment
por: Parasrampuria, Ridhi, et al.
Publicado: (2017)

Pharmacokinetics of Cabotegravir in Subjects with Moderate Hepatic Impairment
por: Shaik, Jafar Sadik, et al.
Publicado: (2017)

Long-Acting Injectable Cabotegravir for HIV Preexposure Prophylaxis Among Sexual and Gender Minorities: Protocol for an Implementation Study
por: Grinsztejn, Beatriz, et al.
Publicado: (2023)

Acute Hepatitis B Infection After a Switch to Long-Acting Cabotegravir and Rilpivirine
por: Pintado, Claire, et al.
Publicado: (2020)

Multicompartmental pharmacokinetic evaluation of long‐acting cabotegravir in healthy adults for HIV preexposure prophylaxis
por: Shaik, Jafar Sadik, et al.
Publicado: (2021)

Is Long-acting Cabotegravir a Pre-exposure Prophylaxis Option for Women of Childbearing Potential?
por: Sahloff, Eric G, et al.
Publicado: (2022)

1599. Real-World Efficacy of Long-Acting Cabotegravir and Rilpivirine in an Urban HIV Clinic
por: Perez, Sarah, et al.
Publicado: (2023)

Pharmacokinetics and antiviral activity of cabotegravir and rilpivirine in cerebrospinal fluid following long-acting injectable administration in HIV-infected adults
por: Letendre, Scott L, et al.
Publicado: (2020)

The potential role of long-acting injectable cabotegravir–rilpivirine in the treatment of HIV in sub-Saharan Africa: a modelling analysis
por: Phillips, Andrew N, et al.
Publicado: (2021)

Injectable Long-Acting Cabotegravir–Rilpivirine Therapy for People Living With HIV/AIDS: Addressing Implementation Barriers From the Start
por: Pinto, Rogério M., et al.
Publicado: (2023)

Characterization of dolutegravir drug resistance in persons diagnosed with HIV after exposure to long-acting injectable cabotegravir for preexposure prophylaxis
por: Ahluwalia, Amrit Kaur, et al.
Publicado: (2022)

A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV
por: Bares, Sara H., et al.
Publicado: (2022)

Safety, Tolerability, Pharmacokinetics, and Acceptability of Oral and Long-Acting Cabotegravir in HIV-Negative Chinese Men
por: Han, Kelong, et al.
Publicado: (2022)

1582. Real-World Use of Long-Acting Cabotegravir + Rilpivirine in the US: Effectiveness in the First Year
por: Sension, Michael G, et al.
Publicado: (2022)

Impact of rilpivirine cross-resistance on long-acting cabotegravir-rilpivirine in low and middle-income countries
por: Steegen, Kim, et al.
Publicado: (2023)

1027. At-Home vs. In-Clinic Receipt of Cabotegravir and Rilpivirine Long-Acting: An Implementation Science Trial
por: Williams, Jamila K, et al.
Publicado: (2023)

Creation of a nanoformulated cabotegravir prodrug with improved antiretroviral profiles
por: Zhou, Tian, et al.
Publicado: (2017)

A Year-Long Extended Release Nanoformulated Cabotegravir Prodrug
por: Kulkarni, Tanmay A., et al.
Publicado: (2020)

The Potential Impact of Long-Acting Cabotegravir for HIV Prevention in South Africa: A Mathematical Modeling Study
por: Smith, Jennifer A, et al.
Publicado: (2020)

Exploring predictors of HIV-1 virologic failure to long-acting cabotegravir and rilpivirine: a multivariable analysis
por: Cutrell, Amy G., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_1j7tmojllk797dgud6hfs2udnk